Day: June 9, 2022

In the Phase III IMpower010 trial, adjuvant Tecentriq reduced the risk of disease recurrence or death by 57% in people with PD-L1 high resected Stage II-III NSCLC, compared with best supportive care Tecentriq is now the first and only cancer immunotherapy available for certain people with early-stage NSCLC in Europe Today’s approval marks Tecentriq’s sixth lung cancer indication in EuropeBasel, 09 June 2022 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Tecentriq® (atezolizumab) as an adjuvant treatment, following complete resection and platinum-based chemotherapy, for adults with non-small cell lung cancer (NSCLC) with a high risk of recurrence* whose tumours express PD-L1≥50% and who do not have EGFR mutant or ALK-positive NSCLC. “Today’s approval represents an important advance,...

Pratteln, Switzerland, and Rockville, MD, USA, June 9, 2022 – Santhera Pharmaceuticals (SIX: SANN) and ReveraGen BioPharma, Inc announce presentations of new data with vamorolone in Duchenne muscular dystrophy (DMD). Cross-study comparisons of long-term efficacy, impact on growth velocity, and frequency and severity of spinal fractures for vamorolone versus current standard of care from the Phase 2b VISION-DMD study and the FOR-DMD study will be presented during the poster session at the 2022 Annual Conference of Parent Project Muscular Dystrophy (PPMD) to be held from June 23-26, 2022, in Scottsdale, AZ, USA. “Data being presented by our academic collaborators at PPMD this year will provide further insight into our understanding of the potential of a dissociative steroid, such as vamorolone, in maintaining muscle strength whilst addressing...

The net asset value (NAV) of EfTEN Real Estate Fund III AS was 19.0549 euros as of 31.05.2022, increasing by 0.8% during May. The net asset value of the EPRA share (EPRA NRV – net book value excluding the deferred income tax liability and the fair value of interest rate derivatives) was 20.24 euros as of 31.05.2022. EPRA NAV also increased by 0.8% in May. In May, the fund earned a total of 1,112 thousand euros in consolidated rental income, which is 10 thousand euros more than a month earlier. The increase is mainly due to the first full month’s rent of the Valkla care home property. The Fund’s consolidated EBITDA was 981 thousand euros in May (April: 963 thousand euros). During the five months of 2022, the fund has earned a total of 5,498 thousand euros in rental income and 4,851 thousand euros in EBITDA, including EBITDA...

Further to our Press Release of 4 May 2022, Awilco Drilling Plc announces that its fully owned subsidiary, Awilco Drilling Offshore (UK) Limited, has now concluded the previously announced sale of the drilling rig WilPhoenix. Concurrent with this transaction, the short-term shareholder loan with Awilhelmsen Offshore AS and QVT Family Office Fund LP has been redeemed. WilHunter, Awilco Drilling’s other semi-submersible, is in the process of being sold for recycling. Aberdeen, 9 June 2022For further information please contact: Eric Jacobs, Interim CEOPhone: +44 1224 737900 Cathrine Haavind, Investor RelationsPhone: +47 93 42 84 64Email: ch@awilcodrilling.com This information is subject of the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

FoundationOne CDx can now be used to identify patients with ROS1 fusion-positive non-small cell lung cancer or patients with NTRK fusion-positive solid tumours for whom treatment with Rozlytrek may be appropriate This approval marks the first and only companion diagnostic indication for Rozlytrek, and another important milestone in tumour-agnostic approaches for people living with rare cancers Roche is a leader in driving personalised healthcare around the world through validated diagnostic tools, genomic insights and a continued focus on drug developmentBasel, 9 June 2022 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the United States Food and Drug Administration (U.S. FDA) has approved Foundation Medicine’s FoundationOne®CDx as a companion diagnostic (CDx) for Roche’s Rozlytrek® (entrectinib). FoundationOne CDx...

The SAI.TECH founder celebrates his second consecutive year to be selected, after having made it onto Forbes 30 under 30 China last year SINGAPORE, June 09, 2022 (GLOBE NEWSWIRE) — Forbes magazine officially announced the Forbes 30 Under 30 Asia Class 2022 recently – For his contributions to innovative Bitcoin mining and energy-saving solutions, Arthur Lee, the 28-year-old founder and CEO of SAI.TECH has made this year’s Forbes 30 Under 30 Asia honorees under the Industry, Manufacturing, and Energy section. Arthur was previously selected to the Forbes 30 under 30 China list in 2021, making this his second consecutive year to be mentioned on the list. Bitcoin mining has always been controversial for the high energy consumption involved in its mining process. According to the data from CCAF (Cambridge Centre for Alternative...